Literature DB >> 24167640

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting.

Andrew Blauvelt1, Marc Brown, Kenneth B Gordon, Arthur Kavanaugh, Craig T Leonardi, Eggert Stockfleth, Bruce Strober, Neil A Swanson, George Martin.   

Abstract

Entities:  

Year:  2013        PMID： 24167640      PMCID： PMC3809592     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN： 1941-2789


× No keyword cloud information.
  72 in total

1.  Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials.

Authors:  T Tzellos; A Kyrgidis; C C Zouboulis
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-03-08       Impact factor: 6.166

Review 2.  Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies.

Authors:  S Prey; C Paul; V Bronsard; E Puzenat; P-A Gourraud; S Aractingi; F Aubin; M Bagot; B Cribier; P Joly; D Jullien; M Le Maitre; M-A Richard-Lallemand; J-P Ortonne
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-04       Impact factor: 6.166

3.  Aggressive squamous carcinomas of the scalp.

Authors:  Pearon G Lang; Martin A Braun; Rajiv Kwatra
Journal:  Dermatol Surg       Date:  2006-09       Impact factor: 3.398

4.  Nonmelanoma skin cancer with perineural invasion: report of outcomes of a case series.

Authors:  Kathryn DeAmbrosis; Brian De'Ambrosis
Journal:  Dermatol Surg       Date:  2009-11-04       Impact factor: 3.398

5.  Prevention initiative for dermatological malignancies: where do we stand?

Authors:  E Stockfleth; B Hinrichs; C Surber; E Christophers
Journal:  Br J Dermatol       Date:  2012-08       Impact factor: 9.302

6.  Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci.

Authors:  David Ellinghaus; Eva Ellinghaus; Rajan P Nair; Philip E Stuart; Tõnu Esko; Andres Metspalu; Sophie Debrus; John V Raelson; Trilokraj Tejasvi; Majid Belouchi; Sarah L West; Jonathan N Barker; Sulev Kõks; Külli Kingo; Tobias Balschun; Orazio Palmieri; Vito Annese; Christian Gieger; H Erich Wichmann; Michael Kabesch; Richard C Trembath; Christopher G Mathew; Gonçalo R Abecasis; Stephan Weidinger; Susanna Nikolaus; Stefan Schreiber; James T Elder; Michael Weichenthal; Michael Nothnagel; Andre Franke
Journal:  Am J Hum Genet       Date:  2012-04-06       Impact factor: 11.025

7.  Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.

Authors:  Jashin J Wu; Kwun-Yee T Poon; Jennifer C Channual; Albert Yuh-Jer Shen
Journal:  Arch Dermatol       Date:  2012-11

8.  Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.

Authors:  K A Papp; C E M Griffiths; K Gordon; M Lebwohl; P O Szapary; Y Wasfi; D Chan; M-C Hsu; V Ho; P D Ghislain; B Strober; K Reich
Journal:  Br J Dermatol       Date:  2013-04       Impact factor: 9.302

9.  Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.

Authors:  Lam C Tsoi; Sarah L Spain; Jo Knight; Eva Ellinghaus; Philip E Stuart; Francesca Capon; Jun Ding; Yanming Li; Trilokraj Tejasvi; Johann E Gudjonsson; Hyun M Kang; Michael H Allen; Ross McManus; Giuseppe Novelli; Lena Samuelsson; Joost Schalkwijk; Mona Ståhle; A David Burden; Catherine H Smith; Michael J Cork; Xavier Estivill; Anne M Bowcock; Gerald G Krueger; Wolfgang Weger; Jane Worthington; Rachid Tazi-Ahnini; Frank O Nestle; Adrian Hayday; Per Hoffmann; Juliane Winkelmann; Cisca Wijmenga; Cordelia Langford; Sarah Edkins; Robert Andrews; Hannah Blackburn; Amy Strange; Gavin Band; Richard D Pearson; Damjan Vukcevic; Chris C A Spencer; Panos Deloukas; Ulrich Mrowietz; Stefan Schreiber; Stephan Weidinger; Sulev Koks; Külli Kingo; Tonu Esko; Andres Metspalu; Henry W Lim; John J Voorhees; Michael Weichenthal; H Erich Wichmann; Vinod Chandran; Cheryl F Rosen; Proton Rahman; Dafna D Gladman; Christopher E M Griffiths; Andre Reis; Juha Kere; Rajan P Nair; Andre Franke; Jonathan N W N Barker; Goncalo R Abecasis; James T Elder; Richard C Trembath
Journal:  Nat Genet       Date:  2012-11-11       Impact factor: 38.330

10.  Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2.

Authors:  Dorothea Muschik; Ilona Braspenning-Wesch; Eggert Stockfleth; Frank Rösl; Thomas G Hofmann; Ingo Nindl
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240
View more
  3 in total

Review 1.  The Role of IL-17 in the Pathogenesis and Treatment of Psoriasis.

Authors:  Joshua A Zeichner; April Armstrong
Journal:  J Clin Aesthet Dermatol       Date:  2016-06-01

Review 2.  Use of biologic agents in combination with other therapies for the treatment of psoriasis.

Authors:  Jennifer C Cather; Jeffrey J Crowley
Journal:  Am J Clin Dermatol       Date:  2014-12       Impact factor: 7.403

Review 3.  New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors.

Authors:  Anthony A Gaspari; Stephen Tyring
Journal:  Dermatol Ther       Date:  2015 Jul-Aug       Impact factor: 2.851
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.